2. Signaling Pathways
  3. Immunology/Inflammation
  4. STING

STING

Stimulator of Interferon Genes; TMEM173; MITA; ERIS; MPYS

STING

Related Products

PDF 0.78 MB

Stimulator of interferon genes (STING) is an integral ER-membrane protein that can be activated by 2'3'-cGAMP synthesized by cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) upon binding of double-stranded DNA. It activates interferon (IFN) and inflammatory cytokine responses to defend against infection by microorganisms.

STING is a key cytosolic receptor for small nucleotides and plays a key role in anticancer and antiviral immunity. STING signaling pathway is also a critical link between innate and adaptive immunity, and induces anti-tumor immune responses. STING agonists, such as endogenous cyclic dinucleotide (CDN) cyclic GMP-AMP (cGAMP), have been used in diverse research for immunogenic tumor clearance, antiviral treatments and vaccine adjuvants.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-148346
    STING agonist-20-Ala-amide-PEG2-C2-NH2
    		Agonist
    STING agonist-20-Ala-amide-PEG2-C2-NH2 is an active scaffold comprising a stimulator of interferon genes (STING). STING agonist-20-Ala-amide-PEG2-C2-NH2 can be used to synthesize immune-stimulating antibody conjugate (ISAC). STING agonist-20-Ala-amide-PEG2-C2-NH2 can be used for the research of cancer.
    STING agonist-20-Ala-amide-PEG2-C2-NH2
  • HY-112921
    diABZI STING agonist-1 (tautomerism)
    		Agonist 99.91%
    diABZI STING agonist-1 tautomerism is a tautomerism of diABZI STING agonist-1 (HY-112921) (compound 3). diABZI STING agonist-1 tautomerism is a selective stimulator of interferon genes (STING) receptor agonist, with EC50s of 130, 186 nM for human and mouse, respectively.
    diABZI STING agonist-1 (tautomerism)
  • HY-152861
    Dazostinag
    		Agonist
    Dazostinag (TAK-676 free base) is an agonist of stimulator of interferon genes (STING) protein with antineoplastic activity. Dazostinag can serve as a playload to synthesis antibody-drug conjugates (ADCs).
    Dazostinag
  • HY-141662
    2',3'-cGAMP-C2-PPA
    		Agonist
    2’,3’-cGAMP-C2-PPA is a cyclic dinucleotide interferon gene-stimulating protein (STING) agonist. 2’,3’-cGAMP-C2-PPA is a drug conjugated conjugate used to target antibody-drug conjugated conjugate (ADC) for the treatment of cancer. 2’,3’-cGAMP-C2-PPA can be used in the study of immune and tumor-related diseases.
    2',3'-cGAMP-C2-PPA
  • HY-111999B
    E7766 disodium
    		Agonist
    E7766 disodium is a macrocycle-bridged STING agonist with a Kd of 40 nM. E7766 disodium shows potent pan-genotypic and antitumor activities.
    E7766 disodium
  • HY-130116
    IACS-8779
    		Agonist
    IACS-8779 is a highly potent stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy.
    IACS-8779
  • HY-130116A
    IACS-8779 disodium
    		Agonist
    IACS-8779 disodium is a highly potent stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy. IACS-8779 disodium shows robust activation of the STING pathway in vitro and a superior systemic anti-tumor response in the B16 murine model of melanoma.
    IACS-8779 disodium
  • HY-152961
    STING agonist-28
    		Agonist
    STING agonist-28 (CF510) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains.
    STING agonist-28
  • HY-153987
    STING agonist-33
    		Agonist 99.67%
    STING agonist-33 (example 1) is an agonist of STING (stimulator of interferon genes) based on 4-ethyl-2-methylthiazole-5-carboxylic acid[1].
    STING agonist-33
  • HY-152957
    STING agonist-24
    		Agonist
    STING agonist-24 (CF504) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains.
    STING agonist-24
  • HY-176126
    STING agonist-42
    		Agonist
    STING agonist-42 (compound 8a) is a potent STING agonist. STING agonist-42 activates STING in THP1 and RAW 264.7 cells with EC50s of 0.06 and 14.15 μM, respectively.
    STING agonist-42
  • HY-150075
    STING agonist-19
    		Agonist
    STING agonist-19 can be used to synthesize ISAC (immune-stimulating antibody conjugates) molecule.
    STING agonist-19
  • HY-153546
    STING agonist-31
    		Agonist
    STING agonist-31 is a STING agonist, with EC50 values of 0.24 and 39.51 μM for h-STING and m-STING. STING agonist-31 has antitumor efficiency.
    STING agonist-31
  • HY-152960
    STING agonist-27
    		Agonist
    STING agonist-27 (CF509) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, exhibits activity against SARS-CoV series strains.
    STING agonist-27
  • HY-143321
    STING agonist-13
    		Agonist
    STING agonist-13 is a stimulator of interferon genes (STING) agonist, for cancer immunity via STING-mediated immune activation. STING agonist-13 can stimulate STING downstream signaling and promoting type I interferon immune responses. STING agonist-13 significantly decreases tumor volume and shows immunological memory-derived cancer inhibition.
    STING agonist-13
  • HY-173404
    VB-85247
    		Agonist
    VB-85247 is a STING agonist. VB-85247 induces upregulation of inflammatory cytokines IFNα/β, TNFα, IL6, and CXCL10, as well as maturation and activation of dendritic cells by activating the STING pathway. VB-85247 can achieve regression of intrabladder tumors and can be used in bladder cancer research.
    VB-85247
  • HY-147834
    STING agonist-9
    		Agonist
    STING agonist-9 (Compound 45) is a potent STING agonist with an EC50 of 1.2 nM and 32.82 μM against h-STING and m-STING, respectively. STING agonist-9 shows antitumor activity.
    STING agonist-9
  • HY-170617
    hSTING agonist-1
    		Agonist
    hSTING agonist-1 (compound 17) is a potent agonist of hSTING. hSTING agonist-1 has poor oral availability. hSTING agonist-1 plays an important role in inflammation research.
    hSTING agonist-1
  • HY-156290
    SAP-04
    		Agonist
    SAP-04 is a potent and orally active STING agonist. SAP-04 exhibits potent immunomodulatory effects for cancer therapy.
    SAP-04
  • HY-174170
    (S)-2-(1-Ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(2-hydroxy-2-phenylethyl)-1H-benzo[d]imidazole-5-carboxamide
    		Agonist
    (S)-2-(1-Ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(2-hydroxy-2-phenylethyl)-1H-benzo[d]imidazole-5-carboxamide (compound 4) is a STING agonist containing a key amide benzimidazole (ABZI) component and shows reproducible inhibition of 3H-cGAMP binding to STING with an apparent inhibition constant IC50 of 14 μM. (S)-2-(1-Ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(2-hydroxy-2-phenylethyl)-1H-benzo[d]imidazole-5-carboxamide can be used for tumor research.
    (S)-2-(1-Ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(2-hydroxy-2-phenylethyl)-1H-benzo[d]imidazole-5-carboxamide
Cat. No. Product Name / Synonyms Application Reactivity